Navigation Links
New approaches to testing cancer drugs needed -- ESMO press commentary
Date:9/30/2013

Lugano, Switzerland, 28th September -- Research institutes, regulators and the pharmaceutical industry are urged to cooperate to develop new approaches to testing cancer drugs, in order to bring the revolution in personalised medicine to patients across Europe, says the European Society for Medical Oncology.

It has become clear in recent years that each patient's cancer has individual characteristics that are potentially amenable to "personalised" treatments that target those characteristics. But there is still a great deal of work to be done to ensure patients benefit from these developments as quickly as possible.

"We are approaching a time when it will be possible to analyse the tumours of many patients to help us select the most appropriate treatment and to personalize treatment," said ESMO spokesperson Marina Garassino of the Division of Medical Oncology at the Italian National Institute of Cancer.

Selecting drugs for individual patients helps avoid useless treatments, minimise toxicity and reduce costs for society. In an ideal situation, oncologists would like to be able to use such methods to ensure every single patient is treated with the best possible drugs, Garassino said.

A major challenge facing researchers is that it is not always feasible to perform the kind of large clinical trials that regulators have demanded in the past to prove the value of new treatments.

"We are used to comparing different treatments using large phase III trials, where thousands of patients are randomized," Garassino explained.

"This is feasible when the disease is frequent but not when we are working with small groups of patients who have particular tumour characteristics. In those cases, we need to work closely with statisticians to develop new methodological approaches."

"Regulatory agencies must take into consideration that these kinds of studies can provide important, reliable information about these new drugs," Garassino said. "ESMO would like to encourage regulatory agencies and governments to implement better strategies in research and drug development. Secondly, we feel it is vital that more educational events are created for patients, to increase their awareness that in 2013 it is possible to personalize treatment for many tumors."

At the European Cancer Congress 2013 today, researchers presented data from an early stage phase II study that illustrated one such approach. In the trial, scientists compared targeted therapy based on molecular profiling against conventional therapy in patients with any type of refractory cancer1.

Patients in the trial have their tumours tested using three different methods, including the assessment of hot spot mutations, gene copy number alterations and expression of oestrogen, progesterone and androgen receptors. Their treatments will be based on these tests, and the primary endpoint will be progression-free survival.

So far, 143 patients have been included in the study, with early results showing that comprehensively profiling the tumour in this way was safe, feasible and compatible with clinical practice. The study authors also found that many tumours carried mutations that made their cancer susceptible to drugs that are already available, Garassino noted.

"This is an important study," Garassino said. "At a time when there are an increasing number of molecular profiling studies being performed, what makes this one particularly noteworthy is that they were able to identify candidate genes when there was already a drug for the selected target."


'/>"/>

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related medicine news :

1. Scripps Florida scientists awarded nearly $1.5 million to develop new approaches to treat cancer
2. GWU consensus report outlines new approaches for evaluating benefits and risks of obesity drugs
3. NIH awards $7.8 million for innovative HIV vaccine approaches
4. As painkiller overdoses mount, researchers outline effective approaches to curb epidemic
5. Cutting-edge approaches to ensuring biologic drug quality focus of forum on bioassays
6. Jan 31 W-2 1099 Form Mailing Deadline Approaches: EzW2 Software Helps Small Businesses Get Form Ready in Time
7. Common Sense Approaches May Stem ICU Delirium
8. Daily-use HIV prevention approaches prove ineffective among women in NIH study
9. New approaches in treating complicated childhood polycystic kidney disease
10. As Summer Approaches, Experts Offer Tips on Preventing Skin Cancer
11. Imprelis Lawsuit News: Minnesota Property Owners Report Imprelis Tree Damage as June 28 Deadline to Opt Out of Imprelis Lawsuit Settlement Approaches, Reports Wright & Schulte
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... Stephanie Hebert Insurance Agency, serving families of ... charity campaign. As part of their ongoing community involvement program, funds are now ... children deserve a voice, and in the spirit of neighbors helping neighbors in ...
(Date:2/8/2016)... ... 2016 , ... Brenton Engineering , powered by Pro ... wrapped products at WestPack 2015, February 9-11, in Anaheim, California. This new solution ... or fully-automatic case packing with a small footprint, rugged, highly flexible, and cost-effective ...
(Date:2/8/2016)... Hilton Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... Head and surrounding areas with a vital new community enrichment program, has teamed up ... to local women and children suffering from intimate abuse. To support all those victimized ...
(Date:2/8/2016)... ... , ... Delta Dental of California and its affiliated companies announced today that ... who recently retired as president and CEO of Delta Dental of California and its ... Year , helped lead the effort to raise funds for studies to strengthen pancreatic ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders ... significant number of women and men with eating disorders report a history of ... predicts the development of an eating disorder. , At the 2016 iaedp ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 8, 2016 /PRNewswire/--  Cell Applications, Inc. and ... services are now available in North ... (3D) bioprinting approach called the "Kenzan Method." Utilizing ... a state-of-the-art robotic system that fabricates 3D tissue ... pay-for-service bio-printing model that makes scaffold-free tissue available ...
(Date:2/8/2016)... Feb. 8, 2016 ... of the "Label-Free Detection Market by ... 2020" report to their offering. ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ...
(Date:2/8/2016)... , Feb. 8, 2016  Astellas Pharma Inc. President and ... promotion of James Robinson as president, Americas Operations, ... in North and South America , effective ... US, representing the commercial organization in the United ... Masao Yoshida , who is retiring in ...
Breaking Medicine Technology: